360Dx

Bio-Rad Q2 Revenues Fall 2 Percent

Aug 03, 2017

This story has been updated from a previous version to include comments made during Bio-Rad's earnings call.

NEW YORK (GenomeWeb) – Bio-Rad reported after the close of the market on Thursday that its second quarter revenues fell 2 percent on both a reported and currency-neutral basis.

For the three months ended June 30, Bio-Rad reported $504.7 million in net sales compared to $516.8 million in the year-ago quarter and short of analysts' average estimate of $515.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Bio-Rad Q2 Revenues Fall 2 Percent

To read the full story....

Breaking News

Todos Medical, Pathnova Partner on Breast Cancer, SARS-CoV-2 Tests

Natera's Signatera ctDNA Test Shows Immunotherapy Response Prediction Capability in Advanced Cancer

Siemens Healthineers Fiscal Q3 Dx Revenues Drop 17 Percent; Firm to Acquire Varian for $16.4B

Siemens Gets First Authorizations for Tests That Estimate Quantities of SARS-CoV-2 Antibodies

Quotient Fiscal Q1 Revenues Up 9 Percent

FDA Grants Emergency Use Authorizations for Zeesan Biotech, UCSD Coronavirus Tests

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

What's Popular?

NIH Awards $249M to Seven Firms for Rapid Acceleration of COVID-19 Diagnostics

SARS-CoV-2 E Gene SNP Raises Concerns About Test Accuracy, Transparency

Facing 'Unfathomable' Demand, Quidel Ramps Up SARS-CoV-2 Test Production

Clinical Reference Laboratory Gets FDA Emergency Use Authorization for COVID-19 Saliva PCR Test

National Labs Focused on Building PCR SARS-CoV-2 Test Capacity in Anticipation of Fall

Sponsorships